| scholarly article | Q13442814 |
| P50 | author | Nicoline Hoogerbrugge | Q56436866 |
| P2093 | author name string | C J A Punt | |
| M Koopman | |||
| J H J M van Krieken | |||
| M J L Ligtenberg | |||
| N F Antonini | |||
| G A M Kortman | |||
| L Mekenkamp | |||
| P2860 | cites work | Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis | Q22122362 |
| Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer | Q28270163 | ||
| A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer | Q28289377 | ||
| Systematic review of microsatellite instability and colorectal cancer prognosis | Q28303189 | ||
| Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines | Q29620526 | ||
| The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas | Q34020549 | ||
| Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial | Q34581085 | ||
| Role of DNA mismatch repair defects in the pathogenesis of human cancer | Q35085461 | ||
| Mismatch repair proficiency and in vitro response to 5-fluorouracil | Q35129256 | ||
| Microsatellite instability and the clinicopathological features of sporadic colorectal cancer | Q35363901 | ||
| Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome | Q35598109 | ||
| Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors | Q35748966 | ||
| BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms | Q35787161 | ||
| New options and old dilemmas in the treatment of patients with advanced colorectal cancer | Q35887568 | ||
| Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer | Q36609603 | ||
| Classification of colorectal cancer based on correlation of clinical, morphological and molecular features | Q36699559 | ||
| Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. | Q36826562 | ||
| Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening | Q37066133 | ||
| Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins | Q38287337 | ||
| Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer | Q38449001 | ||
| Allelic imbalance and microsatellite instability in resected Duke's D colorectal cancer | Q38475125 | ||
| Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. | Q40582817 | ||
| Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma | Q40620362 | ||
| Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status | Q40706999 | ||
| The role of DNA mismatch repair in platinum drug resistance | Q41155820 | ||
| Clues to the pathogenesis of familial colorectal cancer | Q42622043 | ||
| Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group | Q43894713 | ||
| High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection | Q44141769 | ||
| Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. | Q44274945 | ||
| The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition | Q45001869 | ||
| High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies | Q46522716 | ||
| Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial | Q46570394 | ||
| Microsatellite instability and colorectal cancer prognosis. | Q46831092 | ||
| Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability | Q47704165 | ||
| CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. | Q53390493 | ||
| Prognostic significance of microsatellite instability in sporadic colorectal cancer. | Q53639179 | ||
| Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. | Q54694611 | ||
| Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. | Q54703703 | ||
| Adverse Prognostic Effect of Methylation in Colorectal Cancer Is Reversed by Microsatellite Instability | Q56589885 | ||
| Better survival rates in patients with MLH1-associated hereditary colorectal cancer | Q57567998 | ||
| A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: Meeting Highlights and Bethesda Guidelines | Q57978042 | ||
| Prognostic Factors and Analysis of Microsatellite Instability in Resected Pulmonary Metastases From Colorectal Carcinoma | Q60609635 | ||
| Frequency of hereditary colorectal carcinoma | Q69807271 | ||
| Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history | Q72657539 | ||
| Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer | Q73345126 | ||
| Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors | Q77639637 | ||
| Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR | Q80421961 | ||
| Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer | Q80557773 | ||
| Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting | Q81737843 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| colorectal cancer | Q188874 | ||
| DNA mismatch repair | Q2984243 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 266-273 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Deficient mismatch repair system in patients with sporadic advanced colorectal cancer | |
| P478 | volume | 100 |
| Q37203399 | A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment |
| Q36494964 | A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency |
| Q91584700 | A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ |
| Q43206841 | ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer |
| Q52371842 | Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. |
| Q37815610 | Adjuvant colon cancer chemotherapy: where we are and where we'll go. |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q53440447 | Association between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancer. |
| Q90023691 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial |
| Q90604757 | Automated Quantitation of CD8-positive T Cells Predicts Prognosis in Colonic Adenocarcinoma With Mucinous, Signet Ring Cell, or Medullary Differentiation Independent of Mismatch Repair Protein Status |
| Q58806091 | Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition |
| Q37114675 | Biomarker in Colorectal Cancer. |
| Q91754859 | Biomarker-guided therapy for colorectal cancer: strength in complexity |
| Q64881806 | Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. |
| Q37132680 | Biomarkers in advanced colorectal cancer: challenges in translating clinical research into practice |
| Q99580038 | CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival |
| Q64113851 | CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids |
| Q38828624 | Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions |
| Q54581789 | Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. |
| Q37602291 | Chemotherapy, which drugs and when |
| Q35088103 | Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent |
| Q38636430 | Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. |
| Q52659178 | Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. |
| Q91904761 | Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer |
| Q37631539 | Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients. |
| Q92514791 | Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer |
| Q34005870 | Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. |
| Q89868154 | Colon Cancer: A Clinician's Perspective in 2019 |
| Q28647615 | Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach |
| Q57178427 | Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing? |
| Q91682267 | Colorectal metastasis to the gallbladder mimicking a primary gallbladder malignancy: histopathological and molecular characteristics |
| Q55071626 | Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. |
| Q64915364 | Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. |
| Q37710549 | Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. |
| Q92709364 | Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients |
| Q91704285 | Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material |
| Q91876747 | Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients |
| Q57022679 | Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy |
| Q45242086 | Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. |
| Q57806327 | Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer |
| Q64083490 | Cross-platform Data Analysis Reveals a Generic Gene Expression Signature for Microsatellite Instability in Colorectal Cancer |
| Q91830988 | Current and emerging biomarkers in metastatic colorectal cancer |
| Q39172118 | Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie |
| Q42086309 | Current progress in immunotherapy for pancreatic cancer |
| Q91584739 | Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer |
| Q41634316 | DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management? |
| Q26796491 | Deficient mismatch repair: Read all about it (Review) |
| Q35462738 | EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer |
| Q40062688 | Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial. |
| Q37061363 | Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers |
| Q38786707 | From tumour heterogeneity to advances in precision treatment of colorectal cancer |
| Q34568317 | Genomic landscape of metastatic colorectal cancer |
| Q60939319 | How the V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications |
| Q40383388 | Immune checkpoints and immunotherapy for colorectal cancer |
| Q53111596 | Immunotherapy for Colorectal Cancer. |
| Q39218636 | Immunotherapy for colorectal cancer: where are we heading? |
| Q48103017 | Immunotherapy regimens for metastatic colorectal carcinomas |
| Q37842126 | Implementing prognostic and predictive biomarkers in CRC clinical trials |
| Q26772272 | Implications of mismatch repair-deficient status on management of early stage colorectal cancer |
| Q51732351 | Improving diagnosis, prognosis and prediction by using biomarkers in CRC patients (Review). |
| Q57758070 | Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer |
| Q36089548 | Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection. |
| Q35045790 | KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients |
| Q40040773 | Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study |
| Q89782419 | Microsatellite Instability and MMR Genes Abnormalities in Canine Mammary Gland Tumors |
| Q92645700 | Microsatellite instability and protein expression of MLH1 and MSH2 genes in young Mexican patients less than 50 years of age diagnosed with colorectal cancer |
| Q34616565 | Microsatellite instability in colorectal cancer-the stable evidence |
| Q83835402 | Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications |
| Q37929008 | Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome |
| Q38895750 | Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade |
| Q90117036 | Mismatch Repair Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy |
| Q38741029 | Mismatch repair deficiency testing in clinical practice |
| Q37696965 | Mismatch repair deficient colorectal cancer in the era of personalized treatment |
| Q38654591 | Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy. |
| Q34362289 | Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies |
| Q91718987 | Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study |
| Q35578034 | Mitochondrial microsatellite instability in patients with metastatic colorectal cancer |
| Q36813582 | Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. |
| Q39308037 | Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates |
| Q36836733 | Molecular dissection of microsatellite instable colorectal cancer |
| Q38938329 | Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer. |
| Q35836592 | Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications |
| Q33813216 | Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). |
| Q57494108 | Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis |
| Q38727912 | New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer |
| Q50876217 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. |
| Q87857715 | Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer |
| Q33765195 | Optimization of a pentaplex panel for MSI analysis without control DNA in a Brazilian population: correlation with ancestry markers. |
| Q88413794 | Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience |
| Q28262647 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency |
| Q54290348 | Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. |
| Q26738655 | Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options |
| Q38847613 | Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. |
| Q58583909 | Prognostic Value of Mismatch Repair Genes for Patients With Colorectal Cancer: Meta-Analysis |
| Q35583987 | Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery |
| Q34982575 | Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy |
| Q37132721 | Prognostic value of colorectal cancer biomarkers. |
| Q92494955 | Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: A case report |
| Q84836911 | RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance |
| Q89807855 | Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study |
| Q37593573 | Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation |
| Q41105389 | Recent developments in the treatment of metastatic colorectal cancer. |
| Q53081522 | Recent progress in Lynch syndrome and other familial colorectal cancer syndromes. |
| Q36413276 | Reduced rate of copy number aberrations in mucinous colorectal carcinoma |
| Q33794933 | Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers |
| Q28080176 | Role of Deficient Mismatch Repair in the Personalized Management of Colorectal Cancer |
| Q48160519 | Role of family history and tumor location on prognosis of patients with colorectal cancer and synchronous metastases |
| Q92954872 | SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer |
| Q64114423 | Selecting treatment options in refractory metastatic colorectal cancer |
| Q55242470 | Shorter survival in adolescent and young adult patients, compared to adult patients, with stage IV colorectal cancer in Japan. |
| Q52691832 | Strategies for Increasing Pancreatic Tumor Immunogenicity. |
| Q100526092 | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| Q35224176 | Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy |
| Q38961110 | Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. |
| Q92306520 | Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review |
| Q43233321 | The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. |
| Q51737468 | The significance of microsatellite instability in colorectal cancer after controlling for clinicopathological factors. |
| Q102061305 | Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability |
| Q52643529 | Updates on immunotherapy for colorectal cancer. |
| Q28075719 | Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation |
Search more.